Foundation Medicine

fiercebiotech | May 29, 2019

Bayer has teamed up with Foundation Medicine to develop genetic diagnostic tests for several of its cancer therapies-starting with the tissue-agnostic Vitrakvi in solid tumors with TRK fusion mutations.Acquired from Loxo Oncology, Bayer’s Vitrakvi (larotrectinib) was the first targeted cancer drug to be developed and approved specifically for a pan-cancer indication, based not on a tumor’s organ site but on its genetic makeup....

biotech | March 30, 2017

Bristol-Myers Squibb (BMS) will use Foundation Medicine’s genomic profiling and molecular information solutions to identify predictive biomarkers in patients enrolled in clinical trials assessing the pharma giant’s cancer immunotherapies, the companies said today....

Labiotech.eu | January 28, 2020

A Swiss research group has developed tiny plastic particles that could carry gene therapies to the center of the cell with less risk of getting attacked by the immune system than conventional gene therapies. The majority of gene therapies in use today are delivered to the DNA of target cells using viral vectors. While efficient at their job, viral vectors can risk triggering the immune system to destroy them. This can lead to the therapy becoming ineffective....

FierceBiotech | January 27, 2020

Johnson & Johnson is joining the growing ranks of biopharmas, including the likes of Moderna and Gilead Sciences, in trying to create a speedy vaccine for the coronavirus out of China. Over the weekend, we learned of a wider range and more deaths as the new virus, which appears to have come out of Wuhan, China, is doing what these diseases do best: spread. The causes of death have so far been reported as pneumonia, with other reports suggesting most of these have come from those with underly...